(PRESS RELEASE) ESCONDIDO, CA and ALEXANDRIA, VA — TearLab Corporation (privately held), a leader in Ocular Surface Diagnostics and MellingMedical, a CVE-Verified Service-Disabled Veteran-Owned Small Business (SDVOSB), announced an agreement that will empower physicians to more effectively diagnose dry eye disease (DED) among veterans.
DED is a very common condition that causes a variety of symptoms including burning eyes, light sensitivity, and fluctuating or blurred vision. Patients suffering from DED have a decreased quality of life and a reduced ability to carry out their activities of daily living.
“We are excited to bring osmolarity testing to America’s veterans and help support their patient care and therapy decisions,” said Chris Melling, founder and CEO of MellingMedical.
Established in more than 100 studies and publications and with over 20 million tests completed to date, the TearLab Osmolarity System uniquely aids physicians in the diagnosis of dry eye by providing precise, predictive, and objective results in 90 seconds. Leading ophthalmology groups have deemed this test essential in detecting significant ocular surface disease as part of the pre-operative workup.
“Osmolarity testing helps empower physicians with an objective and early detection of DED, and provides them with a faster feedback loop to evaluate the impact of therapeutic decisions over a period of weeks instead of months,2,3” said Adam Szaronos, Chief Commercial Officer of TearLab. “This partnership with MellingMedical now enables veterans and teaching hospitals across the US to access this technology for their patients.”
Contact government@tearlab.com for more information.